Dallas Research Institute

Dallas Research Institute (DRI) is a premier clinical research site based in the Dallas-Fort Worth metroplex, specializing in complex clinical trials for metabolic and liver-related conditions. Founded in 2024 as a joint venture, the institute focuses on therapeutic areas such as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH), obesity, and cardiovascular disorders. DRI is recognized for its strong patient recruitment capabilities, community engagement, and non-invasive diagnostic offerings like FibroScan® liver screenings. In September 2026, the institute was acquired by Summit Clinical Research Solutions through its integrated site network, Pinnacle Clinical Research, to expand its clinical trial operations in the Texas market.